Navigation Links
Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Date:3/11/2008

These results provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

About the phase 3 study: The phase 3 study investigating PI-88 as a post- resection treatment for hepatocellular carcinoma (HCC, primary liver cancer) following curative resection is a double-blinded, placebo-controlled study that has been designed to establish the efficacy and safety of PI-88 in the post-resection HCC setting. The trial will recruit approximately 600 patients at 65-70 hospitals in more than a dozen countries. Disease-free survival is the study's primary endpoint. Upon completion of this trial, the results are expected to form the basis of global regulatory filings for PI-88.

About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has operations in Australia and the US.

Progen Information: Media and Investor Relations

Linton Burns Australia:

Progen Pharmaceuticals Limited Cindy Ingram

T: +61 7 3842 3333 Progen Pharmaceuticals Limited

E: lintonb@progen-pharma.com T: +61 7 3842 3333

E: cindyi@progen-pharma.com

Media Relations USA: Investor Relations USA:

Robert D. Stanislaro Evan Smith

Financial Dynamics Financial Dynamics

T: 212-850-5657 T: 212-850-5606

E: robert.stanislaro@fd.com E: evan.smith@fd.com

This press release contains forward-looking statements that are based on current management expectations. These statements
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
2. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Inclinix Announces New Patent for Expert System Platform
7. Genzyme Announces Presentation of New Positive Data on Carticel(R)
8. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
9. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
(Date:11/24/2008)...swire-FirstCall/ -- Leaders of Schering-Plough Cor...or investors on the company,s research pipeline, h...ncludes 46 new entities in clinical trials or unde... , , "Research and development is adding st...ue our transformation," said Fred Hassan, chairman...
Breaking Medicine Technology:Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 1ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 2ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 3ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 4American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 1American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 2Researchers identify how to switch off cancer cell genes 1186 1Earth Observation essential for geohazard mitigation 1184 1Earth Observation essential for geohazard mitigation 1184 2Earth Observation essential for geohazard mitigation 1184 3
...n,s pipeline provide support for,epigenetic and co...,data on use of Thalidomide to treat multiple myel...tCall/ -- Pharmion,Corporation reported today that...he company,s marketed and pipeline products will b...f Clinical,Oncology,s (ASCO) 43rd Annual Meeting i...
...2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) r...N,241, the Company,s novel investigational mda-7/I...nced solid tumors., The data (Abstract #380), whic...e American Society of Gene Therapy, showed that,in...n all treated,tumors, including in those patients ...
Other Medicine Technology:Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3
(Date:12/1/2008)...swire-USNewswire/ -- Intravenous patient-controlle... own pain medication, but a new study published in...Journal on Quality and Patient Safety shows that ...e likely to result in patient harm than errors tha...udy of more than 9,500 PCA errors over a five-year...
(Date:12/1/2008)...1 Mentice proudly announces,the l...ion training - the,Mentice VIST 7.7 enhanced trai...ns. New features such as vital signs, complication...ality add to the clinical realism and,enhance the... "Features like vital signs and complications imp...
(Date:12/1/2008)...Newswire/ -- Sciton introduces ProLipo,PLUS(TM), ...ered laser system,for ablating and melting unwant...ue tightening. ProLipo PLUS combines 1064 nm and ... sculpting results. Frequently used as an adjunct...zed as a standalone procedure,for patients who ar...
(Date:12/1/2008)...ghlights the cutting-edge of intraoperative imagin...mens Healthcare ( www.siemens.com/healthcare ... ARCADIS(R) C-Arm systems, featuring outstanding i...recision in the OR, at the 94th Scientific Assembl...f North America (RSNA) from November 30 to Decembe...
Breaking Medicine News(10 mins):Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 2Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 3Health News:Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level 2Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 2Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 3
...rs have identified a key receptor that could be a ...f acute respiratory distress syndrome (ARDS). //Th...tening condition. The receptor is similar to wha... taste (G-protein coupled receptors) There is no e...
...e Prime Minister Mr. Man Mohan Singh to take the i...he films and television. // With the ministries of...o reach consensus on modalities for implementing t...ter approached Prime Minister Manmohan Singh to re...
...be able to isolates molecule that would be helpful...volutionary study has been done independently by t...spital Boston and they have identified a master pr...change as a result of individual experiences. Sci...
...rnment on Wednesday for neglecting their duties ac... of Bihar Mr. Nitish Kumar gave the nod for the di...ried out with immediate effect. Last week, the go...edical officers and initiated departmental proceed...
Other Medicine News:
The challenge for Carl Zeiss was to find innovative solutions for measurements on the eye and for preoperative computation of intraocular lenses (IOL). The result of this development work is the IOLM
Ahmed Glaucoma Valve (small size) with Pars Plana Clip .
Ahmed Glaucoma Valve.
...ompatibility is established. Provides a robust and...nsure correct positioning on the globe. Pressure R...h, when covered by Tenons tissue, acts as a Pressu...ive hypotony. The range of implants allows the sur...
Medicine Products: